IVERIC bio ISEE Stock
IVERIC bio Price Chart
IVERIC bio ISEE Financial and Trading Overview
IVERIC bio stock price | 39.48 USD |
Previous Close | 38.14 USD |
Open | 38.2 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 800 |
Day's Range | 38.07 - 38.45 USD |
52 Week Range | 8.95 - 38.99 USD |
Volume | 2.52M USD |
Avg. Volume | 3.72M USD |
Market Cap | 5.3B USD |
Beta (5Y Monthly) | 1.108098 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 39.18 USD |
ISEE Valuation Measures
Enterprise Value | 4.75B USD |
Trailing P/E | N/A |
Forward P/E | -29.33588 |
PEG Ratio (5 yr expected) | 0.54 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 11.055811 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -20.765 |
Trading Information
IVERIC bio Stock Price History
Beta (5Y Monthly) | 1.108098 |
52-Week Change | 308.82% |
S&P500 52-Week Change | 20.43% |
52 Week High | 38.99 USD |
52 Week Low | 8.95 USD |
50-Day Moving Average | 34.9 USD |
200-Day Moving Average | 24.3 USD |
ISEE Share Statistics
Avg. Volume (3 month) | 3.72M USD |
Avg. Daily Volume (10-Days) | 3.37M USD |
Shares Outstanding | 137.98M |
Float | 137.01M |
Short Ratio | 2.44 |
% Held by Insiders | 0.65% |
% Held by Institutions | 109.36% |
Shares Short | 15.07M |
Short % of Float | 10.99% |
Short % of Shares Outstanding | 10.91% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -29.63% |
Return on Equity (ttm) | -55.023% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -117012000 USD |
EBITDA | -228890000 USD |
Net Income Avi to Common (ttm) | -222904000 USD |
Diluted EPS (ttm) | -1.77 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 599.92M USD |
Total Cash Per Share (mrq) | 4.35 USD |
Total Debt (mrq) | 97.76M USD |
Total Debt/Equity (mrq) | 20.49 USD |
Current Ratio (mrq) | 15.532 |
Book Value Per Share (mrq) | 3.476 |
Cash Flow Statement
Operating Cash Flow (ttm) | -176852000 USD |
Levered Free Cash Flow (ttm) | -97539128 USD |
Profile of IVERIC bio
Country | United States |
State | NJ |
City | Parsippany |
Address | 8 Sylvan Way |
ZIP | 07054 |
Phone | 609 474 6755 |
Website | https://ivericbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 163 |
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Q&A For IVERIC bio Stock
What is a current ISEE stock price?
IVERIC bio ISEE stock price today per share is 39.48 USD.
How to purchase IVERIC bio stock?
You can buy ISEE shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for IVERIC bio?
The stock symbol or ticker of IVERIC bio is ISEE.
Which industry does the IVERIC bio company belong to?
The IVERIC bio industry is Biotechnology.
How many shares does IVERIC bio have in circulation?
The max supply of IVERIC bio shares is 134.31M.
What is IVERIC bio Price to Earnings Ratio (PE Ratio)?
IVERIC bio PE Ratio is 0.00000000 now.
What was IVERIC bio earnings per share over the trailing 12 months (TTM)?
IVERIC bio EPS is 0 USD over the trailing 12 months.
Which sector does the IVERIC bio company belong to?
The IVERIC bio sector is Healthcare.
IVERIC bio ISEE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16103.45 USD — |
+0.82
|
4.52B USD — | 16094.17 USD — | 16247.59 USD — | — - | 4.52B USD — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2078.81 USD — |
-0.4
|
— — | 2075.76 USD — | 2093.28 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7837.41 USD — |
+0.85
|
— — | 7832.7 USD — | 7908.95 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4337.34 USD — |
-0.65
|
— — | 4335.84 USD — | 4376.86 USD — | — - | — — |
NASDAQ HealthCare IXHC | 986.88 USD — |
-0.25
|
— — | 986.44 USD — | 994.67 USD — | — - | — — |
Nasdaq US Smart Pharmaceuticals NQSSPH | 1454.2 USD — |
-0.47
|
— — | 1453.71 USD — | 1464.83 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}